This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Genmab Rina-S Ovarian Cancer Safety
Tech clinical trial results

Genmab Rina-S Ovarian Cancer Safety

Analysis based on 8 articles · First reported Apr 13, 2026 · Last updated Apr 13, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive safety data for Genmab's Rinatabart sesutecan in combination with Bevacizumab for advanced Ovarian cancer could lead to increased investor confidence in Genmab and the broader biotechnology sector focused on oncology. This development suggests potential for new treatment options, which could positively impact the market for cancer therapeutics.

Biotechnology Pharmaceuticals
Event Summary

Genmab announced new data from its Phase 1/2 RAINFOL-01 study, demonstrating that rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate, in combination with Bevacizumab, showed a tolerable safety profile with no new safety signals in patients with advanced Ovarian cancer. The results were presented at the 2026 Society of Gynecologic Oncology Annual Meeting. This positive safety data supports the continued late-stage clinical development of Rinatabart sesutecan, including ongoing Phase 3 trials for recurrent platinum-sensitive and platinum-resistant Ovarian cancer, as well as endometrial and non-small cell lung cancer. The combination therapy was well-tolerated, with manageable adverse events consistent with the known profiles of the individual agents.

Entities Involved
stock
Genmab
Genmab announced positive safety data from its Phase 1/2 RAINFOL-01 trial for Rina-S in combination with bevacizumab for advanced ovarian cancer, supporting further development of its investigational drug.
Importance 100.0 Sentiment 70.0
per
Cara Mathews
Cara Mathews, a study investigator, commented on the potential of Rinatabart sesutecan to be safely combined with Bevacizumab, offering more options for advanced ovarian cancer.
Importance 20.0 Sentiment 0.0
per
Tahamtan Ahmadi
Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer at Genmab, highlighted the growing clinical evidence supporting Rinatabart sesutecan's development and its potential to expand treatment possibilities.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.